Compare DK & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | TNGX |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2017 | 2020 |
| Metric | DK | TNGX |
|---|---|---|
| Price | $34.94 | $13.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $35.41 | $14.33 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $42,069,000.00 |
| Revenue This Year | N/A | $52.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.17 |
| 52 Week Low | $11.03 | $1.04 |
| 52 Week High | $43.50 | $13.48 |
| Indicator | DK | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 63.84 |
| Support Level | $29.34 | $6.33 |
| Resistance Level | $35.45 | N/A |
| Average True Range (ATR) | 1.89 | 0.77 |
| MACD | 0.18 | -0.04 |
| Stochastic Oscillator | 77.89 | 92.93 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has two segments: Refining segment and Logistics segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.